Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2021 Filed Feb 19, 2021 21:21 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 2,343 | $211.82 | $496,294.26 |
DisclosureSEC source: 0001209191-21-012355 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,196 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.82 (range $211.15 to $212.14). Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:21 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 584 | $210.05 | $122,669.20 |
DisclosureSEC source: 0001209191-21-012355 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,539 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.05 (range $209.59 to $210.37). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 6,240 | $211.75 | $1,321,320.00 |
DisclosureSEC source: 0001209191-21-012320 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,858 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:08 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 6,240 | $211.75 | $1,321,320.00 |
DisclosureSEC source: 0001209191-21-012328 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,460 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:12 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 2,080 | $211.75 | $440,440.00 |
DisclosureSEC source: 0001209191-21-012334 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,541 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 13,970 | $211.75 | $2,958,147.50 |
DisclosureSEC source: 0001209191-21-012344 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,676 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:18 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Tax withholdingCommon Stock | 6,240 | $211.75 | $1,321,320.00 |
DisclosureSEC source: 0001209191-21-012347 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,106 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 7,613 | $211.75 | $1,612,052.75 |
DisclosureSEC source: 0001209191-21-012352 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,929 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:21 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 2,740 | $211.75 | $580,195.00 |
DisclosureSEC source: 0001209191-21-012355 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,123 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:24 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 2,000 | $211.75 | $423,500.00 |
DisclosureSEC source: 0001209191-21-012360 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,468 Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:02 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 500 | $211.67 | $105,835.00 |
DisclosureSEC source: 0001209191-21-010691 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,098 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.67 (range $211.25 to $212.21). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:02 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 4,783 | $210.42 | $1,006,438.86 |
DisclosureSEC source: 0001209191-21-010691 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,598 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.42 (range $209.91 to $210.89). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:07 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 200 | $212.10 | $42,420.00 |
DisclosureSEC source: 0001209191-21-010697 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,700 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $212.10 (range $211.99 to $212.21). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:07 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 600 | $211.19 | $126,714.00 |
DisclosureSEC source: 0001209191-21-010697 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,900 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.19 (range $210.86 to $211.66). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:07 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 4,356 | $210.39 | $916,458.84 |
DisclosureSEC source: 0001209191-21-010697 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.39 (range $209.85 to $210.83). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 200 | $211.97 | $42,394.00 |
DisclosureSEC source: 0001209191-21-010703 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,346 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $211.97 (range $211.97 to $211.98). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 300 | $211.21 | $63,363.00 |
DisclosureSEC source: 0001209191-21-010703 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,546 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.21 (range $210.97 to $211.33). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:15 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 3,818 | $210.43 | $803,421.74 |
DisclosureSEC source: 0001209191-21-010703 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,846 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.43 (range $209.95 to $210.94). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 100 | $211.98 | $21,198.00 |
DisclosureSEC source: 0001209191-21-010723 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,542 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 500 | $211.22 | $105,610.00 |
DisclosureSEC source: 0001209191-21-010723 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,642 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.22 (range $210.92 to $211.87). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:20 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 3,860 | $210.43 | $812,259.80 |
DisclosureSEC source: 0001209191-21-010723 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,142 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.43 (range $209.89 to $210.87). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:22 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 217 | $211.41 | $45,875.97 |
DisclosureSEC source: 0001209191-21-010733 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,864 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.41 (range $211.17 to $211.50). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:22 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 1,469 | $210.44 | $309,136.36 |
DisclosureSEC source: 0001209191-21-010733 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,081 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.44 (range $210.06 to $210.90). F3 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:24 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 210 | $211.32 | $44,377.20 |
DisclosureSEC source: 0001209191-21-010739 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,863 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.32 (range $211.10 to $211.50). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:24 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
SaleCommon Stock | 1,288 | $210.45 | $271,059.60 |
DisclosureSEC source: 0001209191-21-010739 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,073 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.45 (range $209.91 to $210.77). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:02 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 2,974 | $214.16 | $636,911.84 |
DisclosureSEC source: 0001209191-21-010087 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,381 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:04 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 3,101 | $214.16 | $664,110.16 |
DisclosureSEC source: 0001209191-21-010092 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,856 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:06 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 2,367 | $214.16 | $506,916.72 |
DisclosureSEC source: 0001209191-21-010095 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,575 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:07 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 2,962 | $214.16 | $634,341.92 |
DisclosureSEC source: 0001209191-21-010098 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,621 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:10 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 13,954 | $214.16 | $2,988,388.64 |
DisclosureSEC source: 0001209191-21-010108 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,646 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:12 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Tax withholdingCommon Stock | 2,563 | $214.16 | $548,892.08 |
DisclosureSEC source: 0001209191-21-010112 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,664 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:13 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 2,421 | $214.16 | $518,481.36 |
DisclosureSEC source: 0001209191-21-010115 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,002 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:14 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 1,344 | $214.16 | $287,831.04 |
DisclosureSEC source: 0001209191-21-010118 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,550 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:16 UTC |
Silva Paul MSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 651 | $214.16 | $139,418.16 |
DisclosureSEC source: 0001209191-21-010125 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,361 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:17 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 1,230 | $214.16 | $263,416.80 |
DisclosureSEC source: 0001209191-21-010129 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,468 Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:19 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 2,365 | $214.16 | $506,488.40 |
DisclosureSEC source: 0001209191-21-010133 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,773 Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:44 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Exercise / conversionCommon Stock · Derivative | 1,930 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-21-009033 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,930 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:44 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
SaleCommon Stock | 1,930 | $215.00 | $414,950.00 |
DisclosureSEC source: 0001209191-21-009033 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,227 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 00:44 UTC |
Parini MichaelEVP, Chief Adm, Leg & BD Off
|
Exercise / conversionCommon Stock | 1,930 | $86.52 | $166,983.60 |
DisclosureSEC source: 0001209191-21-009033 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, Chief Adm, Leg & BD Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:42 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 11,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008093 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,355 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:42 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 12,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008093 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,728 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:42 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008093 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,340 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,554 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · derivative · entry 12 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,554 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 89 | $216.83 | $19,297.87 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 10 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,957 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 90 | $215.80 | $19,422.00 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 9 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,046 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 242 | $214.98 | $52,025.16 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 8 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,136 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $214.98 (range $214.72 to $215.36). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 497 | $213.90 | $106,308.30 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,378 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $213.90 (range $213.49 to $214.17). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 488 | $212.77 | $103,831.76 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,875 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $212.77 (range $212.29 to $213.20). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 148 | $211.22 | $31,260.56 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,363 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $211.22 (range $211.06 to $211.27). F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:43 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 1,554 | $86.52 | $134,452.08 |
DisclosureSEC source: 0001209191-21-008101 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.